Delta Pharma, Inc.: An FDA-Registered 503B Outsourcing Facility
Delta Pharma, Inc. is a United States-based entity operating within the Biotech and Life Sciences sector, specifically registered as a 503B Outsourcing Facility. This designation places the company squarely in the pharmaceutical manufacturing and compounding space, with a critical focus on providing high-quality, sterile, and non-sterile medications in large batches to institutional healthcare providers. The company's operations are predicated on adherence to strict regulatory standards, differentiating it from traditional compounding pharmacies.
What the Company Does
Delta Pharma, Inc.'s core function is the large-batch manufacturing and compounding of essential drug products for the institutional healthcare market, including hospitals, clinics, and physician offices. Unlike traditional compounding pharmacies (known as 503A pharmacies) which primarily prepare patient-specific prescriptions, a 503B Outsourcing Facility like Delta Pharma is authorized to manufacture compounded medications in bulk without individual prescriptions. This model is designed to support the continuous operational needs of healthcare systems.
A key aspect of the company's mission is to act as a reliable partner in the national healthcare supply chain. This includes a crucial role during periods of drug shortages, where its FDA authorization allows the facility to quickly step in and supply unavailable medications. This capability helps to ensure that essential patient care remains uninterrupted at client institutions.
Products and Services
Delta Pharma???s offerings are categorized by the products it compounds and the essential services it provides to maintain a compliant and reliable supply chain for its clients.
The company maintains a portfolio of essential, ready-to-administer sterile products. The focus is on compounded sterile preparations (CSPs) that are vital for hospital and clinical use, often to meet specific dosage, concentration, or formulation needs not available from conventional drug manufacturers.
Product Category: The products are primarily compounded sterile preparations (CSPs), which include injectables, IV solutions, and other parenteral medications. As a 503B facility, the products must be compounded using active pharmaceutical ingredients (APIs) from the FDA's 503B Bulks List or for drugs currently on the FDA's drug shortage list.
Ready-to-Administer Formulations: A significant value-add is the production of ready-to-administer forms, such as pre-filled syringes or pre-filled IV bags. These formats are critical for patient safety and efficiency, as they reduce the need for in-house manipulation by hospital staff, thus minimizing the risk of medication error and contamination at the point of care.
Examples of Compounded Steriles (General Type): Historically, the facility has produced compounded sterile injectable products, exemplified by preparations such as triamcinolone and lidocaine (Deltalone-40), which are representative of the complex sterile compounding work performed by 503B facilities. The portfolio continuously evolves to address current clinical needs and drug shortages.
2. Services: Bulk Compounding and Regulatory Assurance
The fundamental service provided by Delta Pharma is its capacity for high-volume, precision compounding under a rigorous quality system, which is the cornerstone of the 503B framework.
Large-Batch Manufacturing (Bulk Compounding): The facility specializes in the high-throughput production of sterile and non-sterile compounded drugs, allowing large healthcare systems to consistently procure essential medications at scale. This ensures a steady supply that is not dependent on the immediate needs of individual patients.
Current Good Manufacturing Practices (cGMP) Compliance: As a registered 503B outsourcing facility, Delta Pharma is mandated to follow cGMP requirements set forth by the FDA. This regulatory compliance is a critical service assurance for clients. It involves rigorous, standardized controls over manufacturing processes, facility design, equipment, testing, and documentation to ensure the identity, strength, quality, and purity of all compounded drugs.
Quality Control and Testing: All products are subject to stringent quality control, including testing for sterility, purity, and strength of the active pharmaceutical ingredients (APIs) before release. This adherence to cGMP-level quality standards is the primary value proposition distinguishing 503B facilities from traditional compounding pharmacies.
Drug Shortage Mitigation: The company provides a formal service function to assist healthcare institutions during national drug shortages by expediting the compounding and distribution of critically needed drugs.
Customer Support and Licensing: Delta Pharma offers dedicated customer service and sales support teams to facilitate seamless ordering and personalized solutions for clients. The company is licensed to operate and ship compounded products to multiple states, actively working to expand its licensing footprint across the US.
In essence, Delta Pharma, Inc. functions as a specialized, cGMP-compliant manufacturing partner within the US pharmaceutical landscape, enabling healthcare providers to manage patient care by ensuring a consistent and compliant supply of ready-to-use, essential sterile medications.
Please note: This information is generated by AI. For legal use, verify with company sources.
